| 2026-05-15 |
详情>>
内部人交易：
ANDREWS DEBORAH J等共交易20笔
|
| 2026-05-13 |
详情>>
股本变动：
变动后总股本4978.85万股
|
| 2026-05-13 |
详情>>
业绩披露：
2026年一季报每股收益0.10美元,归母净利润520.60万美元,同比去年增长109.60%
|
| 2026-05-13 |
财报披露：
美东时间 2026-05-13 盘后发布财报
|
| 2026-05-04 |
股东大会：
将于2026-06-18召开股东大会
会议内容 ▼▲
- 1.Elect the following seven director nominees named in the Proxy Statement for a term of office expiring at the Company’s 2027 annual meeting of shareholders or until their successors are duly elected and qualified: Neal C. Bradsher, Arthur C. Butcher, Wei Jiang, Richard T. LeBuhn, Louis E. Silverman, Christopher M. Wang, and Lilian Y. Zhou
2.Approve an amendment to the Company’s Amended and Restated Omnibus Equity Incentive Plan, as amended, which increases the number of shares of Company common stock that are reserved for issuance under the plan by 3.9 million shares
3.Ratify the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending January 1, 2027
4.Approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers
|
| 2026-03-03 |
详情>>
业绩披露：
2025年年报每股收益-1.62美元,归母净利润-8044.8万美元,同比去年增长-298.1%
|
| 2025-11-05 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.26美元,归母净利润-6213.9万美元,同比去年增长-543.22%
|
| 2025-09-16 |
股东大会：
将于2025-10-23召开股东大会
会议内容 ▼▲
- 1.To consider and vote on the proposal to adopt the Agreement and Plan of Merger, dated as of August 4, 2025 (as it may be amended from time to time, the “Merger Agreement”), by and among STAAR, Alcon Research, LLC, a Delaware limited liability company (“Alcon”), and Rascasse Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Alcon (“Merger Sub,” and such proposal, the “Merger Proposal”). Pursuant to the terms and conditions of the Merger Agreement, Merger Sub will merge with and into STAAR (the “Merger”), with STAAR continuing as the surviving company in the Merger and as a wholly owned subsidiary of Alcon;
2.To consider and vote on the proposal to approve, on an advisory (nonbinding) basis, the compensation that may be paid or become payable to STAAR’s named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement (the “Compensation Proposal”).
|
| 2025-08-06 |
详情>>
业绩披露：
2025年中报每股收益-1.44美元,归母净利润-7102.3万美元,同比去年增长-1858%
|
| 2025-05-07 |
详情>>
业绩披露：
2025年一季报每股收益-1.1美元,归母净利润-5421.1万美元,同比去年增长-1523.57%
|
| 2025-04-24 |
股东大会：
将于2025-06-18召开股东大会
会议内容 ▼▲
- 1.Elect the following six director nominees named in the Proxy Statement for a term of office expiring at the Company’s 2026 annual meeting of shareholders or until their successors are duly elected and qualified: Arthur C. Butcher, Stephen C. Farrell, Wei Jiang, Louis E. Silverman, Elizabeth Yeu, M.D., and Lilian Y. Zhou
2.Ratify the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending January 2, 2026
3.Approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers
|
| 2025-02-21 |
详情>>
业绩披露：
2024年年报每股收益-0.41美元,归母净利润-2020.8万美元,同比去年增长-194.66%
|
| 2024-10-30 |
详情>>
业绩披露：
2024年三季报(累计)每股收益0.29美元,归母净利润1402.00万美元,同比去年增长3.16%
|
| 2024-08-07 |
详情>>
业绩披露：
2024年中报每股收益0.08美元,归母净利润404.00万美元,同比去年增长-53.95%
|
| 2024-05-07 |
详情>>
业绩披露：
2024年一季报每股收益-0.07美元,归母净利润-333.9万美元,同比去年增长-223.21%
|
| 2024-04-24 |
股东大会：
将于2024-06-20召开股东大会
会议内容 ▼▲
- 1.Elect the following seven director nominees named in the Proxy Statement for a term of office expiring at the Company’s 2025 annual meeting of shareholders or until their successors are duly elected and qualified: Arthur C. Butcher, Stephen C. Farrell, Thomas G. Frinzi, Wei Jiang, Aimee S. Weisner, Elizabeth Yeu, M.D., and Lilian Zhou
2.Approve an amendment to the Company’s Amended and Restated Omnibus Equity Incentive Plan, which increases the number of shares of Company common stock that are reserved for issuance under the plan by 2.6 million shares
3.Ratify the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 27, 2024
4.Approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers
|
| 2024-02-27 |
详情>>
业绩披露：
2023年年报每股收益0.44美元,归母净利润2134.70万美元,同比去年增长-46.18%
|
| 2023-04-26 |
股东大会：
将于2023-06-15召开股东大会
会议内容 ▼▲
- 1.Elect the following six director nominees named in the proxy statement for a term of office expiring at the 2024 annual meeting of shareholders or until their successors are duly elected and qualified: Stephen C. Farrell, Thomas G. Frinzi, Gilbert H. Kliman, M.D., Aimee S. Weisner, Elizabeth Yeu, M.D., and K. Peony Yu, M.D.;
2.Approve the Amended and Restated STAAR Surgical Company Omnibus Equity Incentive Plan (the “Restated Plan”) which increases the number of shares of our common stock that are reserved for issuance under the plan by 2.17 million shares, among other changes;
3.Ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending December 29, 2023;
4.Hold a non-binding advisory vote to approve STAAR’s compensation of its named executive officers;
5.Hold a non-binding advisory vote on the frequency of future advisory votes to approve named executive officer compensation;
6.Transact such other business as may properly come before the meeting or any adjournment or postponement of the meeting.
|
| 2022-04-29 |
股东大会：
将于2022-06-16召开股东大会
会议内容 ▼▲
- 1.elect the following seven director nominees named in the proxy statement for a term of office expiring at the 2023 annual meeting of shareholders or until their successors are duly elected and qualified: Stephen C. Farrell, Thomas G. Frinzi, Gilbert H. Kliman, M.D., Caren Mason, Aimee S. Weisner, Elizabeth Yeu, M.D., and K. Peony Yu, M.D.;
2.ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending December 30, 2022;
3.approve an increase in the annual equity award granted to non-employee directors;
4.hold a non-binding advisory vote to approve STAAR’s compensation of its named executive officers;
5.transact such other business as may properly come before the meeting or any adjournment or postponement of the meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-30 |
股东大会：
将于2021-06-24召开股东大会
会议内容 ▼▲
- 1.elect the following seven director nominees named in the proxy statement for a term of office expiring at the 2022 annual meeting of shareholders or until their successors are duly elected and qualified: Stephen C. Farrell, Thomas G. Frinzi, Dr. Gilbert H. Kliman, Caren Mason, Louis E. Silverman, Dr. Elizabeth Yeu, and Dr. K. Peony Yu;
2.ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending December 31, 2021;
3.hold a non-binding advisory vote to approve STAAR’s compensation of its named executive officers;
4.transact such other business as may properly come before the meeting or any adjournment or postponement of the meeting.
|
| 2020-07-14 |
股东大会：
将于2020-07-30召开股东大会
会议内容 ▼▲
- 1.elect the following six director nominees named in the proxy statement for a term of office expiring at the 2021 annual meeting of shareholders or until their successors are duly elected and qualified: Stephen C. Farrell, Thomas Frinzi, Dr. Gilbert H. Kliman, Caren Mason, John C. Moore, and Louis E. Silverman;
2.approve the Amended and Restated STAAR Surgical Company Omnibus Equity Incentive Plan (the “Restated Plan”) which increases the number of shares of our common stock that are reserved for issuance under the plan by 2.65 million shares, among other things;
3.ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending January 1, 2021;
4.hold a non-binding advisory vote to approve STAAR’s compensation of its named executive officers;
5.transact such other business as may properly come before the meeting or any adjournment or postponement of the meeting.
|
| 2019-04-29 |
股东大会：
将于2019-06-20召开股东大会
会议内容 ▼▲
- 1.elect the following five director nominees for a term of office expiring at the 2020 annual meeting of stockholders or until their successors are duly elected and qualified: Stephen C. Farrell, Caren Mason, John C. Moore, Louis E. Silverman, and William P. Wall;
2.ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending January 3, 2020;
3.hold an advisory vote to approve annual compensation program for non-employee directors;
4.hold an advisory vote to approve STAAR’s compensation of its named executive officers;
5.transact such other business as may properly come before the meeting or any adjournment or postponement of the meeting.
|
| 2018-04-26 |
股东大会：
将于2018-06-14召开股东大会
会议内容 ▼▲
- 1.elect the following five director nominees for a term of office expiring at the 2019 annual meeting of stockholders or until their successors are duly elected and qualified: Stephen C. Farrell, Caren Mason, John C. Moore, Louis E. Silverman, and William P. Wall;
2.approve the Amended and Restated STAAR Surgical Company Omnibus Equity Incentive Plan (the “Restated Plan”) which increases the number of shares of our common stock that are reserved for issuance under the plan by 2.235 million shares, among other changes;
3.adopt amendments to the existing Amended and Restated Certificate of Incorporation (the “COI”) to make certain changes reflecting current practices in corporate governance and to make certain ministerial and conforming changes;
4.adopt amendments to the existing Amended and Restated Bylaws (the “Bylaws”) to make certain changes reflecting current practices in corporate governance and to make certain ministerial and conforming changes;
5.adopt amendments to the COI to increase the minimum number of authorized directors from three to five;
6.adopt amendments to the Bylaws to increase the minimum number of authorized directors from three to five;
7.adopt amendments to the COI to reflect that directors may be removed with or without cause;
8.adopt amendments to the Bylaws to reflect that directors may be removed with or without cause;
9.ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending December 28, 2018;
10.hold an advisory vote to approve annual compensation program for non-employee directors and any increase to the annual compensation program by up to 10% over any two-year period;
11.hold an advisory vote to approve STAAR’s compensation of its named executive officers;
12.transact such other business as may properly come before the meeting or any adjournment or postponement of the meeting.
|
| 2017-05-01 |
股东大会：
将于2017-06-13召开股东大会
会议内容 ▼▲
- 1. elect the following five director nominees for a term of office expiring at the 2018 annual meeting of stockholders and until their successors are duly elected and qualified: Stephen C. Farrell, Caren Mason, John C. Moore, Louis E. Silverman, and William P. Wall;
2. adopt amendments to the existing Amended and Restated Certificate of Incorporation (the “COI”) to make certain changes reflecting current practices in corporate governance and to make certain ministerial and conforming changes;
3. adopt amendments to the existing Amended and Restated Bylaws (the “Bylaws”) to make certain changes reflecting current practices in corporate governance and to make certain ministerial and conforming changes;
4. adopt amendments to the COI to increase the minimum number of authorized directors from three to five;
5. adopt amendments to the Bylaws to increase the minimum number of authorized directors from three to five;
6. adopt amendments to the COI to reflect that directors may be removed with or without cause;
7. adopt amendments to the Bylaws to reflect that directors may be removed with or without cause;
8. ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending December 29, 2017;
9. hold an advisory vote to approve STAAR’s compensation of its named executive officers;
10. hold an advisory vote on the frequency of future advisory votes (whether every one, two or three years) to approve named executive officer compensation;
11. transact such other business as may properly come before the meeting or any adjournment or postponement of the meeting.
|